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Abstract
Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-related decisions based
upon evaluations of reinforcement value and response costs. Furthermore, people with major depression and other
disorders often show anergia, psychomotor retardation, fatigue, and alterations in effort-related decision making. Tasks
measuring effort-based decision making can be used as animal models of the motivational symptoms of depression, and
the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor
tetrabenazine. Tetrabenazine induces depressive symptoms in humans, and also preferentially depletes dopamine (DA).
Rats were assessed using a concurrent progressive ratio (PROG)/chow feeding task, in which they can either lever press on a
PROG schedule for preferred high-carbohydrate food, or approach and consume a less-preferred lab chow that is freely
available in the chamber. Previous work has shown that the DA antagonist haloperidol reduced PROG work output on this
task, but did not reduce chow intake, effects that differed substantially from those of reinforcer devaluation or appetite
suppressant drugs. The present work demonstrated that tetrabenazine produced an effort-related shift in responding on
the PROG/chow procedure, reducing lever presses, highest ratio achieved and time spent responding, but not reducing
chow intake. Similar effects were produced by administration of the subtype selective DA antagonists ecopipam (D1) and
eticlopride (D2), but not by the cannabinoid CB1 receptor neutral antagonist and putative appetite suppressant AM 4413,
which suppressed both lever pressing and chow intake. The adenosine A2A antagonist MSX-3, the antidepressant and
catecholamine uptake inhibitor bupropion, and the MAO-B inhibitor deprenyl, all reversed the impairments induced by
tetrabenazine. This work demonstrates the potential utility of the PROG/chow procedure as a rodent model of the effort-
related deficits observed in depressed patients.
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Introduction
Motivation is a complex process that involves multiple
behavioral functions and neural circuits [1–4]. Organisms are
directed towards or away from stimuli, they can respond to
primary motivational stimuli and conditioned cues, and under
some conditions they can demonstrate high levels of behavioral
activation [2,5–8]. One of the manifestations of activational
aspects of motivation is that organisms can show robust activity in
the initiation and maintenance of motivated behavior, leading to
substantial and persistent work output in their instrumental (i.e.,
reinforcer-seeking) actions. Thus, organisms can overcome
response costs separating them from motivational stimuli, and
frequently they must make effort-related decisions based upon
cost/benefit analyses [1,2]. In the last few years, there has been
growing interest in the neural circuitry underlying effort-based
processes, both in animals [2,5,9–15] and humans [16–20].
Forebrain circuits regulating exertion of effort and effort-related
choice behavior involve several structures, including basolateral
amygdala and prefrontal/anterior cingulate cortex [10,14,21],
ventral pallidum [13,22], and nucleus accumbens [5,15,23–26].
Effort-based decision-making is generally studied using tasks
that offer a choice between high effort instrumental actions leading
to more highly valued reinforcers vs. low effort options leading to
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less valued reinforcers. In animal studies, such tasks include a T-
maze task that uses a vertical barrier to provide the effort-related
challenge [23,26,27,28], effort discounting tasks [9,12,29], and
operant behavior procedures that offer animals a choice between
responding on ratio schedules for preferred reinforcers vs.
approaching and consuming a less preferred food [1,30,32].
Several studies in this area have focused on the effort-related
effects of brain dopamine (DA) systems, particularly accumbens
DA. Across multiple tasks, low doses of DA antagonists and
accumbens DA depletions or antagonism shift choice behavior by
decreasing selection of the high effort/high reward option and
increasing selection of the low effort/low reward choice
[5,9,23,26,33]. The effects of DAergic manipulations on effort-
based allocation of responding are not explained by changes in
appetite, food consumption or preference, or discrimination of
reward magnitude [23,30–32,34,35]. Furthermore, the effort-
related effects of DA antagonism can be reversed by co-
administration of adenosine A2A antagonists such as istradefylline,
MSX-3 and MSX-4 [25,27,36–40].
It has been suggested that tasks measuring effort-based decision
making could be used to model the effort-related motivational
symptoms of depression and other disorders [5,15,41–43]. People
with depression and related disorders not only display alterations
in mood or affect, but also can show profound psychomotor/
motivational impairments (e.g. lassitude, anergia, fatigue, psycho-
motor retardation; [5,44–46]). Tests of effort-related decision
making have been developed in humans [47], and recent studies
have shown that people with major depression show reduced
selection of high effort alternatives [48]. The present work
investigated the effort-related effects of tetrabenazine (TBZ),
which is an inhibitor of VMAT-2 (vesicular monoamine trans-
porter- type 2). By inhibiting VMAT-2, TBZ blocks vesicular
storage and depletes monoamines, with its greatest impact being
upon striatal DA [49,50]. TBZ is used to treat Huntington’s
disease, but major side effects include depressive symptoms,
including fatigue [51–53]. TBZ has frequently been used in studies
involving animal models of depression [54–56], and the present
studies assessed the effects of TBZ on performance of a concurrent
progressive ratio (PROG)/chow feeding choice task [32]. With this
task, rats have the choice of lever pressing on a PROG schedule
reinforced by preferred high-carbohydrate pellets vs. approaching
and consuming a less preferred laboratory chow. This choice
procedure is useful because the PROG schedule requires that the
animal repeatedly makes within-session choices between lever
pressing and chow intake under conditions in which the ratio
requirement is gradually increasing. Previous work with this task
demonstrated that the DA D2 family antagonist haloperidol
suppressed PROG lever pressing, highest ratio achieved, and time
spent responding, but did not suppress chow intake [32]. These
effects of DA antagonism differed substantially from administra-
tion of the cannabinoid CB1 inverse agonist and putative appetite
suppressant AM251, and also differed from the effects of reinforcer
devaluation by pre-feeding, both of which substantially suppressed
chow intake under conditions that also reduced lever pressing [32].
As well as studying the effects of TBZ in the present work,
additional drugs were administered so their effects could be
compared with TBZ (the D1 antagonist ecopipam, the D2
antagonist eticlopride, and the CB1 receptor neutral antagonist
AM4113). Finally, several putative and established antidepressant
drugs (the adenosine A2A antagonist MSX-3, the catecholamine
uptake blocker bupropion, the MAO-B inhibitor deprenyl, and the
COMT inhibitor tolcapone) were assessed for their ability to
reverse the effects of TBZ. This work was conducted in order to
work towards the development of animal models of the effort-
related motivational symptoms of depression and other disorders
[5,41,43].
Materials and Methods
Animals
Ninety four adult male Sprague-Dawley rats (Harlan, India-
napolis, IN, USA) were housed in a colony at 23 uC with 12-h
light/dark cycles (lights on at 0:700 h). Rats weighed 300–350 g at
the beginning of the study, and were initially food deprived to 85%
of their free-feeding body weight for training. Rats were fed
supplemental chow to maintain weight throughout the study, with
water available ad libitum in the home cages. Despite food
restriction, rats were allowed modest weight gain (approximately
10%) throughout the experiment, to be consistent with the normal
growth of the animals. All animal protocols were approved by the
University of Connecticut Institutional Animal Care and Use
Committee, and followed NIH guidelines.
Pharmacological Agents and Dose Selection
The VMAT-2 inhibitor tetrabenazine (Tocris Bioscience) was
dissolved in a solution of 20% dimethylsulfoxide (DMSO) and
saline and then titrated with 1N HCl and sonicated until dissolved.
A pH matched vehicle solution of 20% DMSO and saline was
used for the vehicle control for TBZ. The DA D1 antagonist
ecopipam and the DA D2 antagonist eticlopride (Tocris Biosci-
ence) were dissolved in 0.9% saline, which also served as the
vehicle control for these studies. The adenosine A2A antagonist
MSX-3 was synthesized in the laboratory of Christa Mu¨ller
(University of Bonn, Bonn, Germany) and was dissolved in 0.9%
saline solution and then pH adjusted with 1N NaOH to a final pH
of 7.4. Saline served as the vehicle control for MSX-3. The
catecholamine uptake inhibitor bupropion hydrochloride (Alfa
Aesar, Ward Hill, MA) and the MAO-B inhibitor deprenyl
hydrochloride (Tocris Bioscience) were dissolved in 0.9% saline,
which also served as the vehicle control for these studies. The
catechol O-methyl transferase (COMT) inhibitor tolcapone
(Toronto Research Chemicals, Toronto Canada) was dissolved
in 0.9% saline solution and then titrated with Tween 80 and
sonicated until dissolved. Saline was used as the vehicle control for
tolcapone. AM4113 was synthesized in the laboratory of Alex
Makriyannis (Center for Drug Discovery, Northeastern University,
Boston, MA), and was dissolved in DMSO, Tween 80, and 0.9%
saline at a ratio of 1:1:8. All doses were selected based on previous
work [32,35,37,39,57] or from unpublished preliminary studies
from this lab. All drugs were administered intraperitoneally (IP).
Behavioral Procedures
Behavioral sessions were conducted in operant conditioning
chambers (28623623 cm3; Med Associates). Rats were initially
trained to lever press on a continuous reinforcement schedule (30-
min sessions; 45-mg pellets, Bioserve, Frenchtown, NJ, USA) for 1
week, and then were shifted to the PROG schedule (30-min
sessions, 5 days/week) for several additional weeks. For PROG
sessions, the ratio started at FR1 and was increased by one
additional response every time 15 reinforcers were obtained
(FR1615, FR2615, FR3615,…). This schedule included a ‘‘time-
out’’ feature that deactivated the response lever if 2 minutes
elapsed without a ratio being completed. Upon reaching stable
baseline responding (at least 9 weeks), chow was then introduced.
Weighed amounts of laboratory chow (Laboratory Diet, 5P00
Prolab RMH 3000, Purina Mills, St. Louis, MO, USA; typically
15–20 g) were concurrently available on the floor of the chamber
during the PROG sessions. At the end of the session, rats were
Tetrabenazine Progressive Ratio Effort Depression
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removed from the chamber, and food intake was determined by
weighing the remaining food (including spillage). Rats were trained
for an additional 5 weeks so that they could they attain relatively
consistent levels of baseline lever pressing and chow intake, after
which drug testing began. For most baseline days rats did not
receive supplemental feeding, however, over weekends and after
drug tests, rats received supplemental chow in the home cage. On
baseline and drug treatment days, rats normally consumed all the
operant pellets that were delivered during each session.
Experimental Procedures
For all experiments, animals received a vehicle injection 1 week
prior to beginning testing in order to habituate them to being
injected. All experiments used a within-group design in which each
rat received all drug or vehicle treatments (IP) in their particular
experiment in a randomly varied order (each treatment was
received only once, one treatment per week, either on a Thursday
or a Friday). Baseline training sessions (i.e., non-drug) were
conducted 4 days per week.
Experiments 1–4: Effort-related effects of TBZ:
Comparison with other drugs
Experiment 1: Effects of TBZ. On test days, rats (n = 14)
received injections of 0.25, 0.5, 0.75, 1.0 mg/kg TBZ or vehicle,
90 minutes prior to testing.
Experiment 2: Effects of the DA D1 antagonist
ecopipam. On test days, rats (n = 12) received injections of
0.05, 0.1, 0.2 mg/kg ecopipam or vehicle, 30 minutes prior to
testing.
Experiment 3: Effects of the DA D2 antagonist
eticlopride. On test days, rats (n = 16) received injections of
0.02, 0.04, 0.08 mg/kg eticlopride or vehicle, 30 minutes prior to
testing.
Experiment 4: Effects of the cannabinoid CB1 antagonist
and putative appetite suppressant AM4113. On test days,
rats (n = 16) received injections of 4.0, 8.0, 16.0 mg/kg AM4113
or vehicle, 30 minutes prior to testing.
Experiments 5–8: Effort-related effects of TBZ: Reversal
experiments
Experiment 5: Ability of the adenosine A2A antagonist
MSX-3 to reverse the effects of TBZ. On test days, rats
(n = 8) received an injection of 0.75 mg/kg TBZ or vehicle 90
minutes prior to testing and an injection of 0.5, 1.0, 2.0 mg/kg
MSX-3 or vehicle 30 minutes prior to testing.
Experiment 6: Ability of the catecholamine uptake
inhibitor bupropion to reverse the effects of TBZ. On test
days, rats (n = 10) received an injection of 0.75 mg/kg TBZ or
vehicle 90 minutes prior to testing and an injection of 5.0, 10.0,
15.0 mg/kg bupropion or vehicle 30 minutes prior to testing.
Experiment 7: Ability of the MAO-B inhibitor deprenyl to
reverse the effects of TBZ. On test days, rats (n = 10) received
an injection of 0.75 mg/kg TBZ or vehicle 90 minutes prior to
testing and an injection of 2.5, 5.0, 10.0 mg/kg deprenyl or vehicle
30 minutes prior to testing.
Experiment 8: Ability of the COMT inhibitor tolcapone to
reverse the effects of TBZ. On test days, rats (n = 8) received
an injection of 0.75 mg/kg TBZ or vehicle 90 minutes prior to
testing and an injection of 10.0, 20.0, 30.0 mg/kg tolcapone or
vehicle 60 minutes prior to testing.
Statistical Analyses
For each experiment, total number of lever presses, highest ratio
achieved, active lever time (in seconds) and gram quantity of chow
consumption were analyzed with repeated measures ANOVA of
data from the entire group (i.e., both high and low performers). To
determine differences between treatment conditions, non-orthog-
onal planned comparisons using the error term from the overall
ANOVA [58] was used (the number of comparisons was restricted
to the number of conditions minus one). In order to assess
differences between performance groups (high and low perform-
ers), each experimental group was divided in half using a median
split of vehicle lever pressing for that experiment. Using this split,
total number of lever presses, highest ratio achieved, active lever
time and gram quantity of chow consumed were analyzed with
repeated measures factorial ANOVA using performance group as
the between subjects variable (Tables 1 and 2). Interaction effects
and follow-up analyses are presented; a significant interaction
means that the drug treatment effect differed across the
performance groups.
Results
Experiment 1: The VMAT-2 inhibitor TBZ decreases
PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA
revealed a significant effect of treatment on total lever presses
(F[4,52] = 4.204, p,0.05, Figure 1A). Planned comparisons
revealed that total lever presses were significantly decreased at
0.50, 0.75 and 1.0 mg/kg TBZ compared to vehicle (p,0.05).
Repeated measures ANOVA also revealed that there was a
significant effect of TBZ on highest ratio achieved
(F[4,52] = 8.135, p,0.05, Figure 1B). Planned comparisons
showed that highest ratio achieved was significantly decreased at
0.50, 0.75 and 1.0 mg/kg TBZ compared to vehicle (p,0.05).
There also was a significant overall effect of treatment on active
lever time (F[4,52] = 6.549, p,0.05, Figure 1C), with 0.50, 0.75
and 1.0 mg/kg TBZ significantly differing from vehicle (p,0.05).
Repeated measures ANOVA revealed no significant effect of TBZ
on chow consumption (F[4,52] = 2.603, n.s., Figure 1D).
Analyses Separating High and Low
Performers. Additional analyses were performed separating
high and low performers into two separate groups, and using
performance group as a factor in a factorial ANOVA. With these
analyses, a significant performance group x treatment interaction
indicates that the drug treatment effect was different for high vs.
low performers (Table 1). There was a significant performance
group interaction for total lever presses (F[4,48] = 4.242, p,0.05),
highest ratio achieved (F[4,48] = 7.378, p,0.05), active lever time
(F[4,48] = 6.458, p,0.05) and chow consumption
(F[4,48] = 4.296, p,0.05). As a result of these significant
interactions, separate repeated measures ANOVAs were conduct-
ed on each performance group. In high performers, these
additional analyses revealed a significant effect of TBZ on total
lever presses (F[4,24] = 4.247, p,0.05), highest ratio achieved
(F[4,24] = 10.425, p,0.05), active lever time (F[4,24] = 9.828, p,
0.05) and chow consumption(F[4,24] = 5.000, p,0.05). Planned
comparisons revealed that TBZ reduced total lever presses in high
performers at 0.5, 0.75 and 1.0 mg/kg compared to vehicle (p,
0.05), and also reduced highest ratio achieved and active lever
time in high performers at all doses tested compared to vehicle (p,
0.05), but increased chow consumption in high performers at 0.5,
0.75 and 1.0 mg/kg doses compared to vehicle (p,0.05). In
contrast, repeated measures ANOVA revealed that in low
performers, TBZ only affected total lever presses
(F[4,24] = 4.769, p,0.05), with planned comparisons showing
that total lever presses were decreased at 0.75 and 1.0 mg/kg TBZ
compared to vehicle (p,0.05). In addition, when there was a
significant interaction each measure was analyzed at each
treatment level for difference between the high and low
Tetrabenazine Progressive Ratio Effort Depression
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performance groups. These analyses revealed that high responders
lever pressed significantly more on vehicle compared to low
responders (p,0.05), but the performance groups did not differ
after any dose of TBZ. There also were significant performance
group differences for highest ratio achieved after injection of
vehicle and 0.25 mg/kg TBZ (p,0.05), but the performance
groups did not differ at higher doses of TBZ. In addition, there
were performance group differences in active lever time only after
vehicle injections (p,0.05). For chow intake, there were significant
performance group differences after injection of vehicle and
0.25 mg/kg TBZ (p,0.05), but not after higher doses of TBZ.
Experiment 2: The DA D1 antagonist ecopipam decreases
PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA
revealed a significant effect of treatment on total lever presses
(F[3,33] = 6.610, p,0.05, Figure 2A). Planned comparisons
showed that ecopipam significantly decreased total lever presses
at 0.05, 0.1 and 0.2 mg/kg compared to vehicle (p,0.05). There
was a significant effect of treatment on highest ratio achieved
(F[3,33] = 16.134, p,0.05, Figure 2B), with planned comparisons
demonstrating that highest ratio achieved was significantly
decreased at 0.05, 0.1 and 0.2 mg/kg ecopipam compared to
vehicle (p,0.05). There also was a significant effect of treatment
on active lever time (F[3,33] = 5.667, p,0.05, Figure 2C). Active
lever time was significantly decreased at 0.1 and 0.2 mg/kg
ecopipam compared to vehicle (p,0.05, planned comparisons). In
addition, there was a significant effect of treatment on chow
consumption (F[3,33] = 5.426, p,0.05, Figure 2D). Planned
comparisons also revealed that chow consumption was signifi-
cantly increased at 0.1 and 0.2 mg/kg ecopipam compared to
vehicle (p,0.05).
Analyses Separating High and Low
Performers. Repeated measures factorial ANOVA (i.e., sepa-
rating animals by performance group; Table 1) revealed a
significant interaction effect in total lever presses
(F[3,30] = 6.250, p,0.05), and highest ratio achieved
(F[3,30] = 7.873, p,0.05), but not for active lever time
(F[3,30] = 1.442, n.s.) or chow intake (F[3,30] = 2.478, n.s.).
Additional analyses to explore the source of the interactions were
conducted as in experiment 1. In high performers, these analyses
revealed a significant effect of ecopipam on total lever presses
Figure 1. Effects of the VMAT-2 inhibitor and DA depleting agent TBZ on PROG/chow performance. On measures of lever pressing,
mean (+SEM) total lever presses (A), highest ratio achieved (B), and active lever time (measured in seconds, C), TBZ produced significant decreases at
0.5, 0.75 and 1.0 mg/kg. Chow consumption (mean +SEM, in grams) during test sessions was unaffected by any dose tested (D). (* p,0.05, different
from vehicle).
doi:10.1371/journal.pone.0099320.g001
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(F[3,15] = 8.580, p,0.05) and highest ratio achieved
(F[3,15] = 26.690, p,0.05), and planned comparisons demon-
strated that ecopipam decreased total lever presses and highest
ratio achieved in high responders at all doses (p,0.05). In contrast,
for low responders ecopipam only produced effects on highest
ratio achieved (F[3,15] = 4.153, p,0.05), leaving total lever
presses not significantly affected (F[3,15] = 2.159, n.s.). Moreover,
planned comparisons revealed that ecopipam reduced highest
ratio achieved in low responders only at the highest dose (p,0.05).
Another source of the interaction in total lever presses was as
significant difference between performance groups after vehicle
treatment (p,0.05), but not at any dose of ecopipam. Moreover,
analyses of the highest ratio achieved data showed that there were
significant differences between high and low performers under all
treatment conditions (p,0.05).
Experiment 3: The DA D2 antagonist eticlopride
decreases PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA
revealed a significant effect of treatment on total lever presses
(F[3,45] = 4.667, p,0.05, Figure 3A). Planned comparisons
revealed that eticlopride significantly decreased total lever presses
at 0.04 and 0.08 mg/kg compared to vehicle (p,0.05). There also
was a significant effect of treatment on highest ratio achieved
(F[3,45] = 9.973, p,0.05, Figure 3B). Planned comparisons
revealed that eticlopride significantly decreased highest ratio
achieved at 0.04 and 0.08 mg/kg compared to vehicle (p,0.05).
There was a significant overall treatment effect on active lever time
(F[3,45] = 6.947, p,0.05, Figure 3C). Planned comparisons also
showed that active lever time was significantly decreased by
eticlopride at 0.08 mg/kg compared to vehicle (p,0.05). Howev-
er, there was no effect of treatment on chow consumption
(F[3,45] = 1.947, n.s., Figure 3D).
Analyses Separating High and Low Performers. Factorial
ANOVA across performance groups (Table 1) revealed a
significant interaction effect for total lever presses
(F[3,42] = 5.819, p,0.05), highest ratio achieved
(F[3,42] = 7.931, p,0.05), and active lever time (F[3,42] = 8.640,
p,0.05), but not for chow intake (F[3,42] = 0.959, n.s.). Individual
ANOVAs revealed a significant effect of eticlopride on total lever
presses ([3,21] = 5.256, p,0.05), highest ratio achieved
(F[3,21] = 11.334, p,0.05), and active lever time
(F[3,21] = 7.204, p,0.05) in high responders. Planned compari-
sons showed that eticlopride reduced total lever presses, highest
Figure 2. Effects of the DA D1 antagonist ecopipam on PROG/chow performance. On measures of lever pressing, mean (+SEM) total lever
presses (A), highest ratio achieved (B), and active lever time (measured in seconds, C), ecopipam produced significant decreases at 0.1 and 0.2 mg/kg.
Chow consumption (mean +SEM, in grams) during test sessions was unaffected by any dose tested (D). (* p,0.05, different from vehicle).
doi:10.1371/journal.pone.0099320.g002
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ratio achieved and active lever time at both 0.04 and 0.08 mg/kg
doses in high responders (p,0.05). In low responders, there was a
significant effect of eticlopride on total lever presses
(F[3,21] = 6.547, p,0.05) and highest ratio achieved
(F[3,21] = 9.085, p,0.05) but not active lever time
(F[3,21] = 1.872, n.s.), and eticlopride significantly decreased total
lever presses and highest ratio achieved at all doses (planned
comparisons, p,0.05). ANOVAs at each treatment level revealed
that there were significant differences between performance
groups for total lever presses and highest ratio achieved after
injection of vehicle, and 0.02 and 0.4 mg/kg (p,0.05), but not
0.08 mg/kg eticlopride. Moreover, there were significant perfor-
mance group differences after injection of vehicle and 0.02 mg/kg
eticlopride (p,0.05), but not at the 0.04 or 0.08 mg/kg doses.
Experiment 4: The cannabinoid CB1 antagonist AM4113
decreases both lever pressing and chow consumption
Analyses of Total Group. Repeated measures ANOVA
revealed a significant effect of AM4113 on total lever presses
(F[3,45] = 3.496, p,0.05, Figure 4A). Non-orthogonal planned
comparisons demonstrated that AM4113 decreased total lever
presses at 8.0 and 16.0 mg/kg compared to vehicle (p,0.05).
There also was a significant effect of AM4113 on highest ratio
achieved (F[3,45] = 8.511, p,0.05, Figure 4B), and planned
comparisons demonstrated that AM4113 decreased highest ratio
achieved at 8.0 and 16.0 mg/kg compared to vehicle (p,0.05).
Active lever time was not affected by AM4113 (F[3,45] = 0.139,
n.s., Figure 4C), however, there was a significant effect of AM4113
on chow consumption (F[3,45] = 16.559, p,0.05, Figure 4D).
Planned comparisons revealed that AM4113 decreased chow
consumption at 8.0 and 16.0 mg/kg compared to vehicle (p,
0.05).
Analyses Separating High and Low Performers. Factorial
ANOVAs revealed significant performance group x treatment
interaction effects (Table 1) for total lever presses (F[3,42] = 3.487,
p,0.05), and highest ratio achieved (F[3,42] = 5.800, p,0.05), but
no significant interaction for chow consumption (F[3,42] = 0.458,
n.s.) or active lever time (F[3,42] = 0.200, n.s.). Repeated measures
ANOVA revealed a significant effect of AM4113 on total lever
presses (F[3,21] = 4.277, p,0.05) and highest ratio achieved
(F[3,21] = 14.008, p,0.05) in high responders, and planned
comparisons revealed that AM4113 significantly reduced total
lever presses at 4.0 and 8.0 mg.kg doses (p,0.05) while highest
ratio achieved was decreased at all doses (p,0.05) in high
performers. However, there were no significant effects of AM4113
Figure 3. Effects of the DA D2 antagonist eticlopride on PROG/chow performance. Mean (+SEM) total lever presses (A) and highest ratio
achieved (B) were significantly decreased by 0.04 and 0.08 mg/kg of eticlopride. Additionally, active lever time (measured in seconds, C) was
significantly reduced at 0.08 mg/kg eticlopride. Chow consumption (mean +SEM, in grams) during test sessions was unaffected by any dose tested
(D). (* p,0.05, different from vehicle).
doi:10.1371/journal.pone.0099320.g003
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on total lever presses (F[3,21] = 0.580, n.s.) or highest ratio
achieved (F[3,21] = 0.948, n.s.) in low responders, which appears
to be the major source of the interaction for these two variables.
Experiment 5: MSX-3 reverses the effects of TBZ on
PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA
revealed a significant effect of treatment on total lever presses
(F[4,28] = 4.586, p,0.05, Figure 5A). Non-orthogonal planned
comparisons revealed that TBZ significantly decreased total lever
presses compared to vehicle (p,0.05), and that 1.0 and 2.0 mg/kg
MSX-3 plus TBZ significantly increased total lever presses
compared to TBZ alone (p,0.05). There also was a significant
effect of treatment on highest ratio achieved (F[4,28] = 6.867, p,
0.05, Figure 5B). Planned comparisons revealed that TBZ
significantly decreased highest ratio achieved compared to vehicle
(p,0.05), and 1.0 and 2.0 mg/kg MSX-3 plus TBZ significantly
increased highest ratio achieved compared to TBZ alone (p,
0.05). ANOVA showed there was a significant effect of treatment
on active lever time (F[4,28] = 3.862, p,0.05, Figure 5C). TBZ
significantly decreased active lever time compared to vehicle (p,
0.05), and 1.0 and 2.0 mg/kg MSX-3 plus TBZ significantly
differed from TBZ alone (p,0.05). There was no significant
treatment effect for chow consumption (F[4,28] = 0.102, n.s.,
Figure 5D).
Analyses Separating High and Low Performers. There
were significant performance group x treatment interactions for
total lever presses (F[4,24] = 2.769, p = 0.05; Table 2), but not for
highest ratio achieved (F[4,24] = 1.765, n.s.), active lever time
(F[4,24] = 0.655, n.s.), chow consumption (F[4,24] = 0.787, n.s.).
Repeated measures ANOVA revealed a significant effect of
treatment on total lever presses (F[4,12] = 4.950, p,0.05) in high
responders, and planned comparisons revealed that both 1.0 and
2.0 mg/kg doses of MSX-3 were significantly higher than TBZ
alone. In contrast, repeated measures ANOVA revealed no
significant effect of treatment on total lever presses
(F[4,12] = 1.051, n.s.) in low responders. High performers lever
pressed at higher levels compared to low performers under all
treatment conditions.
Experiment 6: Bupropion reverses the effects of TBZ on
PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA
demonstrated a significant effect of treatment on total lever presses
Figure 4. Effects of the cannabinoid CB1 antagonist and putative appetite suppressant AM4113 on PROG/chow performance. Mean
(+SEM) total lever presses (A) and highest ratio achieved (B) were significantly decreased by 16.0 mg/kg of AM4113. Active lever time (measured in
seconds, C) was not affected by AM4113 at any dose tested. Chow consumption (mean +SEM, in grams) was significantly reduced at 4.0, 8.0 and
16.0 mg/kg of AM4113 (D). (* p,0.05, different from vehicle).
doi:10.1371/journal.pone.0099320.g004
Tetrabenazine Progressive Ratio Effort Depression
PLOS ONE | www.plosone.org 9 June 2014 | Volume 9 | Issue 6 | e99320
(F[4,40] = 7.683, p,0.05, Figure 6A). Planned comparisons
revealed that total lever presses were significantly decreased by
TBZ compared to vehicle (p,0.05), and that total lever presses
were significantly increased at 15.0 mg/kg bupropion plus TBZ
compared to TBZ alone (p,0.05). There also was a significant
effect of treatment on highest ratio achieved (F[4,40] = 14.364, p,
0.05, Figure 6B). Planned comparisons showed that highest ratio
achieved was significantly decreased by TBZ compared to vehicle
(p,0.05), and that 15.0 mg/kg bupropion plus vehicle signifi-
cantly differed from TBZ alone (p,0.05). Active lever time also
showed a significant overall effect of treatment (F[4,40] = 5.416,
p,0.05, Figure 6C); this measure was significantly decreased by
TBZ compared to vehicle (p,0.05), and 15.0 mg/kg bupropion
plus TBZ differed from TBZ alone (p,0.05). There was a
significant effect of treatment on chow consumption
(F[4,40] = 9.041, p,0.05, Figure 6D), but the only significant
planned comparison was that chow intake was significantly
decreased by 15.0 mg/kg bupropion compared to TBZ alone
(p,0.05).
Analyses Separating High and Low Performers. There
were significant treatment by performance group interactions
(Table 2) for total lever presses (F[4,32] = 5.730, p,0.05), and
highest ratio achieved (F[4,32] = 4.524, p,0.05), but no significant
interaction for active lever time (F[4,32] = 0.877, n.s.). Further-
more, there was a significant treatment by group interaction in
chow consumption (F[4,32] = 5.334, p,0.05). Repeated measures
ANOVA revealed a significant effect of treatment on total lever
presses (F[4,16] = 7.825, p,0.05), highest ratio achieved
(F[4,16] = 10.989, p,0.05) and chow consumption
(F[4,16] = 12.029, p,0.05) in high performers, with bupropion
significantly increasing total lever presses and highest ratio
achieved and decreasing chow consumption at 15.0 mg/kg
compared to TBZ alone (p,0.05). In low responders, there also
were significant effects of treatment on total lever presses
(F[4,16] = 6.339, p,0.05), highest ratio achieved
Figure 5. The adenosine A2A antagonist MSX-3 reverses the effects of TBZ on the PROG/Chow procedure. On measures of lever
pressing, mean (+SEM) total lever presses (A), highest ratio achieved (B), and active lever time (measured in seconds, C), TBZ produced significant
decreases at 0.75 mg/kg. Chow consumption (mean +SEM, in grams) during test sessions was unaffected by TBZ (D). MSX-3 reversed the effects on
total lever presses, highest ratio achieved and active lever time at both 1.0 and 2.0 mg/kg. (# p,0.05, different from vehicle; * p,0.05, different from
TBZ alone).
doi:10.1371/journal.pone.0099320.g005
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(F[4,16] = 7.111, p,0.05) and chow consumption
(F[4,16] = 2.940, p = 0.05), and planned comparisons with this
group demonstrated that bupropion significantly increased total
lever presses and decreased chow consumption at 15.0 mg/kg (p,
0.05), and increased highest ratio achieved at both 10.0 and
15.0 mg/kg compared to TBZ alone (p,0.05). For total lever
presses, highest ratio achieved and chow intake, there were
significant differences between the high and low performance
groups under all treatment conditions (p,0.05).
Experiment 7: Deprenyl reverses the effects of TBZ on
PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA
showed there was a significant effect of treatment on total lever
presses (F[4,36] = 6.172, p,0.05, Figure 7A). Planned compari-
sons demonstrated that total lever presses were decreased by TBZ
compared to vehicle (p,0.05), and 5.0 mg/kg deprenyl plus TBZ
significantly differed from TBZ alone (p,0.05). There also was a
significant effect of treatment highest ratio achieved
(F[4,36] = 5.176, p,0.05, Figure 7B), with planned comparisons
demonstrating that highest ratio achieved was significantly
decreased by TBZ compared to vehicle (p,0.05), while 5.0 mg/
kg deprenyl plus TBZ significantly differed from TBZ alone (p,
0.05). Active lever time also was significantly affected by drug
treatment (F[4,36] = 3.073, p,0.05, Figure 7C). TBZ significantly
suppressed active lever time compared to vehicle (p,0.05), and all
doses of deprenyl plus TBZ increased active lever time compared
to TBZ alone. In addition, there was a significant effect of
treatment on chow consumption (F[4,36] = 3.039, p,0.05,
Figure 7D), with chow consumption being significantly lower in
the 10.0 mg/kg deprenyl plus TBZ condition compared to TBZ
alone (p,0.05).
Analyses Separating High and Low Performers. Factorial
ANOVAs of each measure revealed a significant treatment x
performance group interaction (Table 2) for total lever presses
(F[4,32] = 9.028, p,0.05), highest ratio achieved (F[4,32] = 5.979,
p,0.05), but not for active lever time (F[4,32] = 1.557, n.s.). In
addition, there was a significant treatment by group interaction in
chow consumption (F[4,32] = 2.911, p,0.05). In high responders,
there were significant treatment effects for total lever presses
(F[4,16] = 11.097, p,0.05) and highest ratio achieved
(F[4,16] = 8.704, p,0.05), but no effect on chow consumption
(F[4,16] = 2.729, n.s.) in high responders. Planned comparisons
revealed that deprenyl significantly increased total lever presses
Figure 6. The DA uptake inhibitor and common antidepressant bupropion reverses the effects of TBZ on the PROG/Chow
procedure. On measures of lever pressing, mean (+SEM) total lever presses (A), highest ratio achieved (B), and active lever time (measured in
seconds, C), TBZ produced significant decreases at 0.75 mg/kg. Chow consumption (mean +SEM, in grams) during test sessions was unaffected by
TBZ (D). Bupropion reversed the effects on total lever presses, highest ratio achieved and active lever time at 15.0 mg/kg. (# p,0.05, different from
vehicle; * p,0.05, different from TBZ alone).
doi:10.1371/journal.pone.0099320.g006
Tetrabenazine Progressive Ratio Effort Depression
PLOS ONE | www.plosone.org 11 June 2014 | Volume 9 | Issue 6 | e99320
and highest ratio achieved in high responders at a dose of 5.0 mg/
kg compared to TBZ alone. In the low responders, there were
significant treatment effects for total lever presses (F[4,16] = 4.677,
p,0.05) and chow consumption (F[4,16] = 7.491, p,0.05) but no
effect on highest ratio achieved (F[4,16] = 1.586, n.s.). In the low
responders, planned comparisons revealed that total lever presses
was significantly increased compared to TBZ alone at the 5.0 mg/
kg dose of deprenyl (p,0.05), and that chow consumption was
significant decreased in low responders at the dose of 10.0 mg/kg
compared to TBZ alone (p,0.05). For total lever presses and
highest ratio achieved, there were significant performance group
differences under the vehicle condition (p,0.05), while for chow
intake the performance groups differed under both the vehicle
condition and the combined treatment of TBZ with 5.0 mg/kg
deprenyl (p,0.05).
Experiment 8: Tolcapone fails to reverse the effects of
TBZ on PROG/chow performanceAnalyses of Total
Group. Repeated measures ANOVA revealed a significant
effect of treatment on total lever presses (F[4,28] = 3.435, p,
0.05, Figure 8A) and highest ratio achieved (F[4,28] = 7.229, p,
0.05, Figure 8B), but no significant effect of treatment on active
lever time (F[4,28] = 2.565, n.s., Figure 8C), or chow consumption
(F[4,28] = 0.458, n.s., Figure 8D). TBZ significantly differed from
vehicle for total lever presses and highest ratio achieved, but
tolcapone failed to significantly reverse any of the effects of TBZ.
Analyses Separating High and Low
Performers. Repeated measures factorial ANOVA revealed
there was a significant treatment by performance group interac-
tion for total lever presses (F[4,24] = 3.023, p,0.05), highest ratio
achieved (F[4,24] = 3.932, p,0.05), and active lever time
(F[4,24] = 2.904, p,0.05), but not chow consumption
(F[4,24] = 0.503, n.s.). There were no significant differences
between TBZ/tolcapone and TBZ/vehicle for any of the
performance groups on any measure.
Discussion
The current studies examined the effects of the VMAT-2
inhibitor and catecholamine depleting agent TBZ on performance
of the PROG/chow feeding choice task in rats. TBZ significantly
decreased total lever presses, highest ratio achieved and active
lever time. In addition, TBZ did not produce an overall significant
effect on chow intake, indicating that appetite for chow
consumption was not suppressed at the doses tested. These effects
of TBZ are consistent with those recently demonstrated in rats
Figure 7. The MAO-B inhibitor and putative antidepressant deprenyl reverses the effects of TBZ on the PROG/Chow procedure. On
measures of lever pressing, mean (+SEM) total lever presses (A), highest ratio achieved (B), and active lever time (measured in seconds, C), TBZ
produced significant decreases at 0.75 mg/kg. Chow consumption (mean +SEM, in grams) during test sessions was unaffected by TBZ (D). Deprenyl
reversed the effects on total lever presses, highest ratio achieved at 5.0 mg/kg. In addition, active lever time was increased at 2.5, 5.0 and 10.0 mg/kg.
Chow consumption was significantly decreased at 10 mg/kg. (# p,0.05, different from vehicle; * p,0.05, different from TBZ alone).
doi:10.1371/journal.pone.0099320.g007
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assessed on a concurrent fixed ratio 5 (FR5)/chow feeding choice
task (i.e., decreased lever pressing and increased chow intake after
TBZ administration; [43]). In addition, Nunes et al. [43] reported
that doses of TBZ up to 1.0 mg/kg had no effect on consumption
of operant pellets or lab chow, and did not alter preference of
pellets over chow, in free feeding preference tests. Thus, it seems
unlikely that the present results with TBZ occurred because of a
change in appetite or food preference. Importantly, these effects
were more pronounced in high performers. High performers
showed decreases in total lever presses at 0.5 mg/kg TBZ whereas
low performers required 0.75 mg/kg in order to show decreases in
total lever presses. Moreover, high performers showed decreases in
highest ratio achieved and active lever time at all doses of TBZ
tested, whereas low performers showed no changes in highest ratio
achieved or active lever time under any dose of TBZ. Finally, high
performers showed increases in chow consumption at 0.5, 0.75
and 1.0 mg/kg TBZ, where low performers showed no change in
chow consumption, presumably because they were already
consuming chow at or near ceiling levels.
Recent research has shown that 0.75 mg/kg TBZ significantly
decreased extracellular DA in nucleus accumbens as measured by
microdialysis [43]. In addition, TBZ affected expression of
phosphorylated DARPP-32 in a manner consistent with reduction
of DA transmission at both D1 and D2 family receptors (43). Thus,
the present experiments also studied the effects of highly selective
D1 and D2 family antagonists. Selective antagonism of D1 or D2
family receptors (via administration of ecopipam or eticlopride,
respectively) produced similar effects to TBZ on the PROG/chow
feeding task, decreasing total lever presses, highest ratio achieved
and active lever time. Neither ecopipam nor eticlopride reduced
chow intake in the dose range tested, and in fact, ecopipam
significantly increased chow intake, which illustrates that there was
a strong shift in effort-related choice from lever pressing to chow
intake. Thus, it appears that reductions in DA transmission at both
D1 and D2 receptors contribute to the effects induced by TBZ.
Taking the present results together with previous studies, it
appears that blockade of either D1 or D2 receptors, or
pharmacological depletion of DA, can reduce PROG lever
pressing and lower break points in a manner that does resemble
the effects of appetite suppression or reinforcer devaluation
[32,43]. Instead of providing a simple measure of ‘‘reward’’,
PROG breakpoints represent the outcome of a cost/benefit
analysis based partially upon characteristics of the reinforcer itself,
but importantly, also on the work-related response costs and time
Figure 8. The COMT inhibitor Tolcapone fails to reverse the effects of TBZ on the PROG/Chow procedure. On measures of lever
pressing, mean (+SEM) total lever presses (A), highest ratio achieved (B), and active lever time (measured in seconds, C), TBZ produced significant
decreases at 0.75 mg/kg. Chow consumption (mean +SEM, in grams) during test sessions was unaffected by TBZ (D). Tolcapone did not reverse the
effects on total lever presses, highest ratio achieved or active lever time at any dose tested (# p,0.05, different from vehicle).
doi:10.1371/journal.pone.0099320.g008
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constraints imposed by the increasing ratio requirements [32].
Together with earlier studies, the results of experiments 1–3
demonstrate that it is exceedingly unlikely that TBZ, ecopipam,
eticlopride and haloperidol are decreasing PROG lever pressing
because of a reduction in primary food motivation, appetite, or the
unconditioned reinforcing properties of food [26,32,43]. Further-
more, these results are consistent with studies showing that
increasing DA transmission by knockdown of the DA transporter
[11] or overexpression of DA D2 receptors in nucleus accumbens
[59] can increase instrumental response output in mice responding
on fixed ratio/chow feeding choice procedures or a PROG
schedule, in a manner that is inconsistent with an alteration of
primary food motivation or the representation of the value of the
food reinforcer.
The effects observed with TBZ or DA receptor blockade
differed substantially from those induced by appetite manipula-
tion, as demonstrated by the effects of the cannabinoid CB1
neutral antagonist and putative appetite suppressant AM4113
[35]. The effects of AM4113 described above were similar to those
observed for the CB1 inverse agonist AM251 [32]; CB1
antagonism decreased chow intake as well as total lever presses
and highest ratio achieved, consistent with previous studies
demonstrating the appetite suppressant effects of these drugs
[32,35]. In the present studies, AM4113 produced greater effects
on lever pressing in high performers compared to low performers.
Specifically, high performers showed decreases in total lever
presses and highest ratio achieved, whereas low performers
showed no change in total lever presses. This pattern of effects
in low performers is likely due to the fact that the low performing
animals get the vast majority of their food from chow intake. The
overall similarity between the actions of a CB1 neutral antagonist
(AM4113) and a CB1 inverse agonist (AM251) suggests that there
is endogenous cannabinoid tone regulating food motivated
behavior, which is attenuated by occupation of CB1 receptors
by the neutral antagonist [35]. Moreover, the present results
highly the utility of choice procedures as compared to conven-
tional PROG schedules, because having chow concurrently
available enables one to differentiate between the effects of low
doses of DA antagonists or TBZ, which leave chow consumption
intact, vs. the appetite suppression induced by interference with
CB1 transmission, which reduces both food reinforced lever
pressing and chow intake.
In recent years, there has been increasing interest in the use of
adenosine A2A antagonists for their potential antidepressant effects
[43,59]. This is supported by studies using traditional animal
models of depression including the forced swim and the tail
suspension tests, in which adenosine A2A antagonists have been
shown to increase swim and struggle time [60,61,62]. Moreover,
several studies have demonstrated the ability of A2A antagonists to
reverse the effects of selective DA antagonism on a variety of
effort-related tasks including the FR5/chow feeding choice task
and the T-maze barrier task [27,25,28,39]. In the present studies,
the adenosine A2A antagonist MSX-3 was capable of reversing the
effects of TBZ, increasing total lever presses, highest ratio achieved
and active lever time. These effects are consistent with TBZ/
MSX-3 reversal studies conducted in rats tested on the FR5/chow
feeding choice procedure [43]. Moreover, these results are
consistent with studies demonstrating the minor-stimulant prop-
erties of adenosine A2A antagonists such as MSX-3, which
increases operant response rates on some schedules of reinforce-
ment [32,57]. In the present studies, the reversal effects produced
by MSX-3 were more pronounced in high performers; in these
animals MSX-3 plus TBZ increased total lever presses, highest
ratio achieved and active lever time relative to TBZ alone. Low
performers on the other hand showed no effect of drug treatments.
It is likely that this pattern of effects is due to the fact that the TBZ
effects on PROG performance are greater in high performers,
which could render those animals more susceptible to reversal.
In addition to testing novel compounds that are putative
antidepressants, it is critical for the development and validation of
the present model that the effects of well characterized antide-
pressants on the PROG/chow feeding choice paradigm should be
assessed. Because TBZ depletes DA, a logical point of focus was on
an antidepressant that works on DA, such as the catecholamine
uptake inhibitor bupropion (Wellbutrin). Bupropion is one of the
most widely prescribed antidepressants [63], and it is one of the
few antidepressants that has shown efficacy in treating the effort-
related symptoms such as fatigue, anergia and psychomotor
retardation in patients with depression and related disorders
[44,46,64–66]. In the current experiments, bupropion was capable
of reversing the effects of TBZ on the PROG/chow procedure,
increasing total lever presses, highest ratio achieved and active
lever time. Moreover, at the highest dose (15.0 mg/kg) it
decreased chow consumption compared to TBZ treated animals.
For both high performers and low performers, bupropion
increased total lever presses, highest ratio achieved and active
lever time compared to TBZ/vehicle, and there also was a
decrease in chow consumption in high performers. These results
are consistent with previous findings on the FR5/chow choice
procedure [43] and the T-maze barrier task (Yohn et al., in
preparation), which also demonstrated the ability of bupropion to
reverse the effects of TBZ administration.
In addition to compounds that block DA uptake such as
bupropion, there has been interest in compounds that block the
enzymatic breakdown of DA for their antidepressant effects. MAO
inhibitors are one group of compounds that have been assessed for
their antidepressant effects. Originally developed as an antipar-
kinsonian drug [67], the MAO-B inhibitor deprenyl has been
shown to have antidepressant effects in humans [68,69], as well as
rodents tested on traditional animal models of depression,
including the forced swim test and inescapable shock paradigm
[70,71]. In view of the fact that nonselective MAO inhibitors have
been used as antidepressants, and deprenyl and related drugs are
recommended for treating akinesia and psychomotor slowing seen
in Parkinson’s disease, it is reasonable to hypothesize that an
MAO-B inhibitor could be useful for the treatment of psychomo-
tor/motivational symptoms. The current studies assessed the
ability of deprenyl to reverse the effects of TBZ on the PROG/
chow feeding choice procedure. Deprenyl was capable of reversing
these effects, increasing total lever presses, highest ratio achieved
and active lever time. In addition, deprenyl decreased chow intake
at the highest dose (10.0 mg/kg) compared to TBZ alone. In
analyzing these results by performance level, it was revealed that
these effects were greater in high performers, who demonstrated
significant deprenyl-induced reversal of the effects of TBZ on total
lever presses, highest ratio achieved and active lever time; low
performers showed little to no effect of deprenyl. As discussed
above, this could be due in part to the fact that TBZ produces
greater effects in high performers, and therefore effects in these
animals are easier to reverse.
COMT inhibitors are another group of drugs that act to block
the enzymatic breakdown of DA, and thus could have effects on
effort-related decision making. There is some clinical evidence of
increased COMT levels in depressed patients [72]. Moreover,
there is evidence for genetic variations in the COMT gene that
could lead to abnormal COMT function [73]. The COMT
inhibitor tolcapone has been used clinically in Parkinson’s patients
to effectively treat their effort-related depressive symptoms [45].
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The current studies sought to assess tolcapone for its ability to
reverse the effort-related impairments induced by TBZ on the
PROG/chow task. As described above, tolcapone failed to reverse
the effects of TBZ on any measure of PROG/chow performance
in the dose range tested. One explanation for this lack of effect
comes from clinical studies demonstrating that improvements in
energy-related symptoms following tolcapone treatment in Par-
kinson’s patients were in the presence of L-DOPA/carbidopa
treatment [74]. This suggests that tolcapone may be more effective
at reversing the effects of TBZ if it is co-administered with other
drugs that stimulate DA transmission, such as L-DOPA or
bupropion. In addition, it has been suggested that COMT plays
a more important role in prefrontal cortex, where the DA
transporter is sparse, compared to striatum, where the DA
transporter is abundant; such a pattern has been interpreted to
mean that COMT exerts a greater effect on prefrontal cortex DA
metabolism, while MAO exerts a greater effects on striatal DA
metabolism [75,76]. Furthermore, there is evidence from COMT
knockout mice showing that COMT has little effect, if any, on
striatal DA levels [77]. When you consider these findings in the
context of clinical studies demonstrating that entacapone, a
peripherally restricted COMT inhibitor, also has been shown to
be effective at treating depressive symptoms when co-administered
with L-DOPA [78,79], it seems possible that the antidepressant
effects of COMT inhibition are due to blockade of peripheral
breakdown of L-DOPA, increasing the amount that reaches the
CNS. In fact, L-DOPA has been shown to improve effort-related
symptoms in depressed patients [80].
In conclusion, TBZ alters effort-related choice behavior,
reducing various indices of PROG lever pressing at doses that
did not suppress chow intake. In fact, TBZ increased chow intake
in rats with high levels of lever pressing performance. The ability
of TBZ to affect effort-based decision making is consistent with
research showing that other manipulations associated with
depression, including stress [81], and administration of pro-
inflammatory cytokines [42], which can induce fatigue-related
symptoms in animals and humans [42,82,83], also can alter effort-
based choice. The effects of TBZ on PROG output were reversed
by co-administration of the adenosine A2A antagonist MSX-3, as
well as two drugs that have been used as antidepressants in
humans (i.e., bupropion and deprenyl). Additional studies should
investigate the effort-related effects of antidepressant drugs with
different pharmacological profiles. However, it also should be
emphasized that tests of effort-related decision making in rodents
are not designed to serve as animal models of depression, in the
broadest sense of the term. Rather, they are being investigated as
potential models of a group of symptoms (i.e., effort-related
psychomotor/motivational symptoms) that is characteristic of
depression [44–47,84,85], but also is seen across multiple
disorders, including conditions associated with high levels of pro-
inflammatory cytokines [42,82,83], schizophrenia [86–90], and
Parkinson’s disease [91]. This suggestion is consistent with recent
approaches in mental health research and theory that place less
emphasis on traditional diagnostic categories or disorders, and
instead focus on the neural circuits mediating specific pathological
symptoms (i.e., the Research Domain Criteria or RDoC approach;
[42,92]).
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